Physician profile
Sameer Rohatgi
NPI 1831118066
$6,908.47
in general payments reported to CMS, 2019-2025
39 companies · $1,338 in 2025
The $1,338 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $654 · 2020: $265 · 2021: $664 · 2022: $1,747 · 2023: $922 · 2024: $1,320 · 2025: $1,338.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,579.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,579.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $1,851.42 | 2019-2024 | Sapien 3 Ultra Resilia, Pascal, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $723.54 | 2021-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $400.44 | 2019-2025 | |
| Boston Scientific Corporation | $395.16 | 2019-2025 | Watchman Flx, General - Ep |
| Abbott Laboratories | $333.10 | 2020-2025 | Navitor, Mitraclip, Aveir |
| Medtronic, INC. | $317.07 | 2022-2024 | Corevalve Evolut R, Ffrangio |
| Amgen INC. | $301.27 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $283.34 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $235.08 | 2019-2025 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $176.82 | 2019-2023 | Jardiance |
| Alnylam Pharmaceuticals INC. | $176.78 | 2023-2025 | Onpattro, Amvuttra |
| Janssen Pharmaceuticals, INC | $166.84 | 2019-2024 | Xarelto |
| Abiomed | $140.03 | 2024-2025 | Impella |
| Astrazeneca Pharmaceuticals LP | $137.14 | 2019-2025 | Wainua, Lokelma |
| Cardiva Medical, INC. | $132.38 | 2020-2023 | Cardiva Vascade Mvp Vvcs 6-12f |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $125.33 | 2019-2023 | |
| Actelion Pharmaceuticals US, INC. | $96.83 | 2020-2024 | Opsumit, Uptravi |
| Scpharmaceuticals INC. | $94.42 | 2023-2025 | |
| Novo Nordisk INC | $89.15 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Teleflex LLC | $75.48 | 2022-2023 | Turnpike |
| Medtronic Vascular, INC. | $70.73 | 2020 | |
| Penumbra, INC. | $68.74 | 2019-2025 | Indigo System |
| Merck Sharp & Dohme LLC | $64.29 | 2022-2025 | Verquvo |
| Kestra Medical Technology Services, INC. | $60.70 | 2025 | Assure Wcd |
| Philips North America LLC | $51.85 | 2025 | Mcot, Diagnostic Ecg Service |
| Heartflow, INC. | $43.06 | 2024-2025 | |
| Lundbeck LLC | $34.52 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $34.39 | 2024-2025 | |
| Amarin Pharma, INC. | $30.29 | 2019 | |
| Terumo Medical Corporation | $24.98 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $23.70 | 2024 | |
| Becton, Dickinson and Company | $23.23 | 2025 | Arista |
| Shockwave Medical, INC | $22.20 | 2022 | |
| Cvrx, INC. | $22.17 | 2024 | Barostim Neo System |
| Kiniksa Pharmaceuticals International, Plc | $20.88 | 2024 | Arcalyst |
| Irhythm Technologies, INC. | $19.39 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $14.86 | 2019 | |
| Bridgebio Pharma, INC. | $13.87 | 2025 | Attruby |
| Ethicon US, LLC | $13.00 | 2023 | Surgicel Nu-Knit, Stratafix, Dermabond |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sameer Rohatgi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.